Greenwich LifeSciences, Inc. (GLSI) Stock Price & Analysis

Greenwich LifeSciences, Inc. (GLSI) is trading at USD 20.08, up 7.35% today, as of November 18, 2026 at 17:13 UTC (US market open; quotes may be delayed), according to Nexqual market data.

GLSI last closed at USD 18.7; today's session has ranged USD 18.24–21.22 on volume of 420,435 shares. Market capitalization is $294.67M, with a 52-week range of USD 7.78–34.1 (NCM). Source: Nexqual, retrieved November 18, 2026 at 17:14 UTC.

What changed for GLSI since Aug 31, 2025

The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

Also available as compact Markdown for AI agents: nexqual.com/GLSI.md

Key facts (GLSI)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GLSI)

USDFY2021FY2022FY2023FY2024FY2025TTM
Operating income-$4.6M-$8.0M-$9.3M-$17.6M-$19.4M-$24.8M
Net income-$4.6M-$7.8M-$8.9M-$17.4M-$19.4M-$24.6M
EPS (diluted)-$0.35-$0.61-$0.69-$1.34-$1.43—
Cash + short-term investments$27.2M$13.5M$7.0M$4.1M$6.2M—

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (GLSI)

Earnings yield -8.34%

Insider purchases (SEC Form 4, open-market, last ~7 months) (GLSI)

3 purchases, $97K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Trade dateInsiderRoleSharesValueAvg priceInsider type
2026-07-28…2026-07-29Patel SnehalCEO and CFO2,200$30K13.43Routine (bought in Apr each year 2023–2025; this trade is outside those months)
2026-07-27Patel SnehalCEO and CFO1,500$20K13.62Routine (bought in Apr each year 2023–2025; this trade is outside those months)
2026-07-23…2026-07-24Patel SnehalCEO and CFO3,600$47K13.06Routine (bought in Apr each year 2023–2025; this trade is outside those months)

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (GLSI)

Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 57.5 (low 45, high 70).

Total return (dividends reinvested) (GLSI)

1Y (from 2025-11-18)5Y (from 2021-11-15)
Total return+143.6%-42.4%
S&P 500 (SPY)+11.8%+66.5%
Per year+143.8%-10.4%
Volatility (annualized)110.3%68.4%
Max drawdown-61.9% (Jan 2026→Jul 2026)-78.9% (Nov 2021→Jun 2022)

Dividends (GLSI)

GLSI paid no cash dividend in the last five years.

Short interest (GLSI)

1,578,166 shares sold short, 20.64% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 1,580,950 shares (-0.2%). Days to cover: 11.5 (short shares ÷ average daily volume).

GLSI earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
—Quarter ended Sep 30, 2026−$0.40−$0.33Miss −21.2%—
—Quarter ended Jun 30, 2026−$0.27−$0.33Beat +18.2%—
—Quarter ended Mar 31, 2026−$0.39−$0.35Miss −11.4%—
—Quarter ended Dec 31, 2025−$0.58−$0.32Miss −81.3%—

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

GLSI recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 16, 202610-QQuarterly report · period ended Sep 30, 2026
Oct 26, 2026DEFA14AAdditional proxy material
Oct 26, 2026DEF 14AProxy statement (pay, board, votes) · period ended Oct 26, 2026
Aug 11, 202610-QQuarterly report · period ended Jun 30, 2026

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

GLSI analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Dec 2026)$-0.42$-0.35−$0.07$02
Next quarter (ends Mar 2027)$-0.43$-0.30−$0.13$02
Current fiscal year (ends Dec 2026)$-1.48$-1.39−$0.09$02
Next fiscal year (ends Dec 2027)$-1.80$-1.17−$0.63$02

Key Statistics (as of November 18, 2026 at 17:14 UTC)

PriceUSD 20.08
Change▲ 7.35% (up)
Previous CloseUSD 18.7
OpenUSD 18.6
Day RangeUSD 18.24 – 21.22
52-Week RangeUSD 7.78 – 34.1
Volume420,435 shares
Market Cap$294.67M
ExchangeNCM

Technical Analysis (GLSI)

Nexqual's technical model rates GLSI "BUY" based on 5 bullish and 2 bearish signals across 129 daily candles, as of November 18, 2026 at 17:14 UTC.

Overall SignalBUY
RSI (14)62.1 (neutral)
vs SMA50Above (USD 16.68)
MACD0.16 (positive)

Analyst Ratings (GLSI)

Wall Street analysts rate GLSI "Buy" based on 2 analysts, with a mean price target of USD 57.5 (range USD 45–70), per Nexqual as of November 18, 2026 at 17:14 UTC.

Consensus RatingBuy
Analyst Count2
Mean TargetUSD 57.5
High TargetUSD 70
Low TargetUSD 45
Buy / Hold / Sell2 / 0 / 0

Earnings (GLSI)

Next Earnings Date2026-11-16
Revenue Estimate$0

Recent Earnings History

QuarterActual vs Estimate
2026-09-30USD -0.4 vs est -0.34 ▼ miss
2026-06-30USD -0.27 vs est -0.33 ▲ beat
2026-03-31USD -0.39 vs est -0.35 ▼ miss
2025-12-31USD -0.58 vs est -0.32 ▼ miss

Source: Nexqual, November 18, 2026 at 17:14 UTC.

Financials & Fundamentals (GLSI)

Gross Margin+0.00%
Operating Margin+0.00%
Profit Margin+0.00%
ROE-11218.13%
Current Ratio0.77
Total Cash$5.90M
Total Debt$0

Source: Nexqual, November 18, 2026 at 17:14 UTC.

Financial Health Score (GLSI)

Nexqual rates Greenwich LifeSciences, Inc.'s overall financial health "Weak" across five dimensions, as of November 18, 2026 at 17:14 UTC.

GrowthMixed — No data
ProfitabilityWeak — Pre-revenue or very early stage
Balance SheetMixed — $6M cash, no debt
Cash FlowWeak — Operating cash flow -$10M (FY ended Dec 2025, 10-K)
EfficiencyCritical — ROE not meaningful (negative equity); ROA -416.6% (last 4 quarters, SEC)

Ownership (GLSI)

Insider Ownership+47.91%
Institutional Ownership+12.45%
Shares Outstanding14.68M
Float7.65M
Short % of Float+20.64%

Source: Nexqual, November 18, 2026 at 17:14 UTC.

Leadership (GLSI)

Greenwich LifeSciences, Inc. is led by Snehal S. Patel, CEO, CFO & Director, per Nexqual as of November 18, 2026 at 17:14 UTC.

CEO, CFO & DirectorSnehal S. Patel
Founder & Independent DirectorEric Rothe
Chief Medical Officer & DirectorFrank Joseph Daugherty
Vice President Clinical & Regulatory AffairsJaye L. Thompson

Major Backers & Investors (GLSI)

Notable institutional backers of Greenwich LifeSciences, Inc. include Fidelity, Goldman Sachs, STRS Ohio, according to Nexqual as of November 18, 2026 at 17:14 UTC.

Active Investors

InvestorStake
Fidelity0.74%
Goldman Sachs0.39%
STRS Ohio0.24%

Index Funds (Passive)

FundStake
BlackRock3.49%
Vanguard Group2.96%
Geode Capital1.28%
State Street1.09%
Northern Trust0.56%
BNY Mellon0.33%

Source: Nexqual, November 18, 2026 at 17:14 UTC.

From Greenwich LifeSciences, Inc.'s Latest SEC 10-K Filing (filed 2026-06-01)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
KODKodiak Sciences IncUSD 96.52▼ 0.29%
BLTEBelite Bio, IncUSD 158.13▲ 0.26%
ORKAOruka Therapeutics, Inc.USD 96.47▲ 0.16%
IBRXImmunityBio, Inc.USD 6.65▲ 6.23%
IMVTImmunovant, Inc.USD 33.47▲ 0.78%
CGONCG Oncology, Inc.USD 81.42▲ 3.14%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 17:14 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt